

65. (amended) The isolated [MHC] Major Histocompatibility Complex Class II immunogenic derivative of tyrosinase of claim 64, wherein said derivative is selected from the group consisting of QNILLSNAPLGPQFP (Ty 56-70) (SEQ ID NO: 1), NILLSNAPLGPQFP (Ty 57-70) (SEQ ID NO: 2) DYSYLQDSDPDSFQD (Ty 448-462) (SEQ ID NO: 6), YSYLQDSDPDSFQD (Ty 449-462) (SEQ ID NO: 13), SYLQDSDPDSFQD (Ty 450-462) (SEQ ID NO: 14), YLQDSDPDSFQD (Ty 451-462) (SEQ ID NO: 37) and LQDSDPDSFQD (Ty 452-462) (SEQ ID NO: 38).

66. (amended) An isolated [MHC] Major Histocompatibility Complex Class II immunogenic derivative of tyrosinase, wherein said derivative comprises at least a 9 amino acid segment of a sequence selected from the group consisting of QNILLSNAPVGPQFP (Ty 56-70, L65→V) (SEQ ID NO: 3), QNILLSNVPVGPQFP (Ty 56-70, A63→V and L65→V) (SEQ ID NO: 4), QNILLSNVPLGPQFP (Ty 56-70, A63→V) (SEQ ID NO: 5), DYSYLQDSDPDSSQD (Ty 448-462, F460→S) (SEQ ID NO: 7), DQSYLQDSDPDSFQD (Ty 448-462, Y449→Q) (SEQ ID NO: 8), DFSYLQDSDPDSFQD (Ty 448-462, Y449→F) (SEQ ID NO: 9), DYSFLQDSDPDSFQD (Ty 448-462, Y451→F) (SEQ ID NO: 10), DYSYLQDSVPDSFQD (Ty 448-462, D456→V) (SEQ ID NO: 11) and SYLQDSVPDSFQD (Ty 450-462, D456→V) (SEQ ID NO: 12).

67. (amended) An isolated [MHC] Major Histocompatibility Complex Class II immunogenic derivative of tyrosinase, wherein said derivative is selected from the group consisting of QNILLSNAPVGPQFP (Ty 56-70, L65→V) (SEQ ID NO: 3), QNILLSNVPVGPQFP (Ty 56-70, A63→V and L65→V) (SEQ ID NO: 4), QNILLSNVPLGPQFP (Ty 56-70, A63→V) (SEQ ID NO: 5), DYSYLQDSDPDSSQD (Ty 448-462, F460→S) (SEQ ID NO: 7), DQSYLQDSDPDSFQD (Ty 448-462, Y449→Q) (SEQ ID NO: 8), DFSYLQDSDPDSFQD (Ty 448-462, Y449→F) (SEQ ID NO: 9), DYSFLQDSDPDSFQD (Ty 448-462, Y451→F) (SEQ ID NO: 10), DYSYLQDSVPDSFQD (Ty 448-462, D456→V) (SEQ ID NO: 11) SYLQDSVPDSFQD (Ty 450-462, D456→V) (SEQ ID NO: 12),

QNFLLSNAPLGPQFP (Ty 56-70, I58→F) (SEQ ID NO: 18), QNVLLSNAPLGPQFP (Ty 56-70, I58→V) (SEQ ID NO: 19), QNILQSNAPLGPQFP (Ty 56-70, L60→Q) (SEQ ID NO: 23), QNILFSNAPLGPQFP (Ty 56-70, L60→F) (SEQ ID NO: 24), QNILVSNAPLGPQFP (Ty 56-70, L60→V) (SEQ ID NO: 25), QNILLSNAVLGPQFP (Ty 56-70, P64→V) (SEQ ID NO: 28), QNILLSNAPQGPQFP (Ty 56-70, L65→Q) (SEQ ID NO: 29), DYSQLQDSDPDSFQD (Ty 448-462, Y451→Q) (SEQ ID NO: 34), DYSYQQDSDPDSFQD (Ty 448-462, L452→Q) (SEQ ID NO: 35), DYSYFQDSDPDSFQD (Ty 448-462, L452→F) (SEQ ID NO: 36).

68. (amended) An immunogenic peptide derivative of [tyrosine] tyrosinase comprising a core binding sequence of formula [X<sub>1</sub>LLX<sub>2</sub>NX<sub>3</sub>X<sub>4</sub>LX<sub>5</sub> (SEQ ID NO: 15) or X<sub>1</sub>LQX<sub>2</sub>SX<sub>3</sub>X<sub>4</sub>DX<sub>5</sub> (SEQ ID NO: 16)] X<sub>1</sub>LLSNX<sub>2</sub>PLG and X<sub>1</sub>LQDSX<sub>2</sub>PDS wherein:

X<sub>1</sub> is selected from the group consisting of methionine, leucine, isoleucine, tyrosine, valine, tryptophan and phenylalanine;

X<sub>2</sub> is selected from the group consisting of [phenylalanine, tryptophan, leucine, isoleucine, alanine, valine, aspartic acid and glutamic acid;

X<sub>3</sub> is selected from the group consisting of] methionine, leucine, threonine, isoleucine, serine and valine[;

X<sub>4</sub> is selected from the group consisting of aspartic acid, alanine, serine, valine, histidine, proline, asparagine, methionine, threonine, leucine and isoleucine; and

X<sub>5</sub> is selected from the group consisting of alanine, serine, glutamine, glycine, leucine, valine and threonine].

69.(amended) The immunogenic peptide of claim 64 wherein said peptide is recognized by human leukocyte antigen (HLA)-DR-restricted CD4<sup>+</sup> T lymphocytes.

70. (amended) The immunogenic peptide of claim 66 wherein said peptide is recognized by human leukocyte antigen (HLA)-DR-restricted CD4<sup>+</sup> T lymphocytes.

71. (amended) The immunogenic peptide of claim 68 wherein said peptide is recognized by human leukocyte antigen (HLA) DR-restricted CD4+ T lymphocytes.

72. (amended) The immunogenic peptide of claim 64 linked to a [MHC] Major Histocompatibility Complex Class II molecule.

73. (amended) The immunogenic peptide of claim 65 linked to a [MHC] Major Histocompatibility Complex Class II molecule.

74. (amended) The immunogenic peptide of claim 66 linked to a [MHC] Major Histocompatibility Complex Class II molecule.

75. (amended) The immunogenic peptide of claim 67 linked to a [MHC] Major Histocompatibility Complex Class II molecule.

76. (amended) The immunogenic peptide of claim 68 linked to a [MHC] Major Histocompatibility Complex Class II molecule.

77. (amended) The immunogenic peptide-[MHC] Major Histocompatibility Complex [complex] of claim 72 wherein said [MHC] Major Histocompatibility Complex Class II molecule is the  $\beta$  chain of the [MHC] Major Histocompatibility Complex Class II molecule.

78. (amended) The immunogenic peptide-[MHC] Major Histocompatibility Complex [complex] of claim 74 wherein said [MHC] Major Histocompatibility Complex Class II molecule is the  $\beta$  chain of the [MHC] Major Histocompatibility Complex Class II molecule.

79. (amended) The immunogenic peptide-[MHC] Major Histocompatibility Complex [complex] of claim 76 wherein said [MHC] Major Histocompatibility Complex Class II molecule is the  $\beta$  chain of the [MHC] Major Histocompatibility Complex Class II molecule.